Akers BioSciences Regains Compliance with Nasdaq Listing Standards
December 11 2019 - 9:30AM
Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer
of rapid health information technologies, announced today that on
December 10, 2019, it received notice from the Hearings Advisor of
the Nasdaq Office of General Counsel that the Company successfully
regained compliance with the minimum bid price requirements set
forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on
the Nasdaq Capital Market and that the Company is in compliance
with all other applicable listing standards. Therefore, the
Company’s scheduled hearing before the Nasdaq Hearing Panel has
been cancelled and the Company’s common stock will continue to be
listed and trade on The Nasdaq Stock Market.
About Akers Biosciences Inc.
Akers Biosciences, Inc. develops, manufactures,
and supplies rapid, point of care screening and testing products
designed to bring health related information directly to the
patient or clinician in a timely and cost-efficient manner.
Forward-Looking Statements
Statements in this press release relating to
plans, strategies, trends, specific activities or investments, and
other statements that are not descriptions of historical facts and
may be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include the need for
additional financing, and any risks detailed from time to time in
Akers' reports filed with the Securities and Exchange Commission,
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and
Current Reports on Form 8-K. Forward-looking statements may be
identified by terms such as "may," "will," "expects," "plans,"
"intends," "estimates," "potential," or "continue," or similar
terms or the negative of these terms. Although Akers believes the
expectations reflected in the forward-looking statements are
reasonable, they cannot guarantee that future results, levels of
activity, performance or achievements will be obtained. Akers does
not have any obligation to update these forward-looking statements
other than as required by law.
Additional information on the company and its
products can be found at www.akersbio.com.
Contact:Investor Relations: Hayden
IR
Brett Mass,
Managing Partner
Phone: (646) 536-7331
Email:
brett@haydenir.com www.haydenir.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024